DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/465lcj/chemokine) has announced the addition of the "Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2015" report to their offering.
Inflammatory immune response requires the recruitment of leukocytes to the site of inflammation upon foreign insult. Chemokines are small chemoattractant peptides that provide directional cues for the cell trafficking and thus are vital for protective host response. In addition, chemokines regulate plethora of biological processes of hematopoietic cells to lead cellular activation, differentiation and survival.
There are today 173 companies plus partners developing 224 chemokine signaling pathway targeting drugs in 961 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 118 drugs.
Chemokine Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 165 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 159 out of the 161 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 32 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 14
- Pre-registration - 2
- Phase III - 21
- Phase II - 84
- Phase I - 109
- Preclinical - 133
- No Data - 5
- Suspended - 2
- Ceased - 118
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/465lcj/chemokine